All In Biotech

Free tool

FAERS Monitor: Sucraid

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 020772 or its brand name (Sucraid, Sacrosidase). Reports on generic versions are filed under their own applications.

Reports

181

Serious

30

17% of reports

Hospitalization

14

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea36
  • abdominal pain35
  • drug ineffective22
  • nausea21
  • abdominal distension19
  • flatulence17
  • headache12
  • product quality issue12
  • dizziness11
  • vomiting11
  • fatigue9
  • insomnia9
  • constipation8
  • product taste abnormal8
  • decreased appetite7

Reports by year received

View as table
YearReports
20091
20132
20143
20152
201635
20171
20186
20193
20202
20212
202212
202331
202437
202525
202619

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product taste abnormalSignal868.734.9468
flatulenceSignal1734.822.2527
abdominal distensionSignal1921.213.8347
abdominal painSignal3517.513.0533
product quality issueSignal1210.35.992
diarrhoeaSignal366.54.8167
constipationSignal84.32.217
insomniaSignal93.92.117
decreased appetiteSignal73.51.710
nauseaSignal213.12.129
vomitingSignal112.71.511
dizzinessSignal112.61.49
headacheSignal122.21.37
drug ineffective221.91.310
fatigue91.30.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.